IFNG and acute myeloid leukemia: A recent study based on the analysis of primary AML blasts of AML patients relapsed after hematopoietic stem cell transplantation incubated in vitro with flotetuzumab or of refractory/relapsed AML patients treated in vivo with flotetuzumab showed an increase in major histocompatibility class II (MHC-II) expression induced by IFN-γ production [93].